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Abstract
Background: Survivin is a dual functioning protein. It inhibits the apoptosis of cancer cells by inhibiting caspases, and 
also promotes cancer cell growth by stabilizing microtubules during mitosis. Since the molecular chaperone Hsp90 
binds and stabilizes survivin, it is widely believed that down-regulation of survivin is one of the important therapeutic 
functions of Hsp90 inhibitors such as the phase III clinically trialed compound 17-AAG. However, Hsp90 interferes with 
a number of molecules that up-regulate the intracellular level of survivin, raising the question that clinical use of Hsp90 
inhibitors may indirectly induce survivin expression and subsequently enhance cancer anti-drug responses. The 
purpose of this study is to determine whether targeting Hsp90 can alter survivin expression differently in different 
cancer cell lines and to explore possible mechanisms that cause the alteration in survivin expression.
Results: Here, we demonstrated that Hsp90 inhibitors, geldanamycin and 17-AAG, induced the over-expression of 
survivin in three different human cancer cell lines as shown by Western blotting. Increased survivin mRNA transcripts 
were observed in 17-AAG and geldanamycin-treated HT-29 and HONE-1 cancer cells. Interestingly, real-time PCR and 
translation inhibition studies revealed that survivin was over-expressed partially through the up-regulation of protein 
translation instead of gene transcription in A549 cancer cells. In addition, 17-AAG-treated A549, HONE-1 and HT-29 
cells showed reduced proteasomal activity while inhibition of 26S proteasome activity further increased the amount of 
survivin protein in cells. At the functional level, down-regulation of survivin by siRNA further increased the drug 
sensitivity to 17-AAG in the tested cancer cell lines.
Conclusions: We showed for the first time that down-regulation of survivin is not a definite therapeutic function of 
Hsp90 inhibitors. Instead, targeting Hsp90 with small molecule inhibitors will induce the over-expression of survivin in 
certain cancer cell lines and subsequently enhances the ability of cell survival in drug-treated situations. The current 
study suggests that dual inhibition of Hsp90 and survivin may be warranted.
Introduction
Heat shock protein 90 (Hsp90) is a molecular chaperone
that assists the correct folding and stabilization of various
proteins in cells. During the last decade, Hsp90 has
emerged as an exciting target for cancer therapy. The
over-expression of Hsp90 has been shown in various can-
cers such as non-small cell lung cancer, oesophageal
squamous cell carcinoma, pancreatic carcinoma and
advanced malignant melanoma [1-4]. In addition, studies
showed that Hsp90 stabilizes various key oncogenic pro-
teins such as survivin, Akt, Erb-2 and HIF-1α in cancer
cells [5-7]. Therefore, targeting hsp90 gives therapeutic
advantages over other target-therapies as multiple
Hsp90-related oncogenic proteins can be targeted simul-
taneously [7].
* Correspondence: jychang@nhri.org.tw
1 National Institute of Cancer Research, National Health Research Institutes 
(NHRI), Tainan 70456, Taiwan ROC
† Contributed equally
Full list of author information is available at the end of the articleBioMed Central
© 2010 Cheung et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Cheung et al. Molecular Cancer 2010, 9:77
http://www.molecular-cancer.com/content/9/1/77
Page 2 of 11Survivin is a member of the inhibitors of apoptosis
(IAPs) family. Unlike other IAPs, survivin is a bifunc-
tional protein that functions as a key regulator of mitosis
and inhibitor of programmed cell death. It is well-demon-
strated that the over-expression of survivin induces resis-
tance to various anti-cancer therapies such as
chemotherapy and radiation therapy in cancer cells [8-
12]. For example, over-expression of survivin has been
shown to induce drug resistance against anti-mitotic
compounds by stabilizing microtubule network in vin-
cristine/colchicine-resistant oral cancer cells and down-
regulation of it restores drug sensitivity to those com-
pounds in the same cell line [9]. In addition, literature
revealed that over-expression of survivin attenuated both
tamoxifen and cisplatin-induced apoptosis in human
breast cancer cells and gastric cancer cells respectively
[10,12]. Interestingly, a recent report suggests that over-
expression of survivin may also enhance DNA double-
strand breaks (DBD) repair capability in radiation-treated
oral cancer cells by up-regulating the molecular sensor of
DNA damage, Ku70 [11]. In clinical situations, the level
of survivin expression was shown to be inversely related
to the levels of apoptosis and positively related to the risk
of local tumor recurrence in rectal cancer patients treated
with radiotherapy [13]. Furthermore, patients with gas-
tric tumors that express lower level of survivin seems to
have a longer mean survival time than patients with
higher survivin expression level after cisplatin treatment
[12]. It has also been shown that survivin expression is
associated with human prostate cancer bone metastasis
[14]. Thus, survivin plays an important role in tumori-
genesis, tumor metastasis and may act as an indicator of
therapeutic effectiveness.
It is widely believed that Hsp90 physically interacts and
stabilizes survivin in cells [5,15,16]. Although Hsp90 is a
molecular chaperone that assists the correct folding of
various proteins in cells, it does not bind to unfolded sur-
vivin [5]. Instead, Hsp90 binds to the mature form of sur-
vivin [5]. Structurally, the amino acid sequence Lys-70-
Lys-90 of survivin is important for the binding to the N-
terminal domain (ATP-binding site) of Hsp90 [5]. Various
studies have investigated the possibility of targeting sur-
vivin using Hsp90 inhibitors, based on the fact that sur-
vivin is important for cancer survival and progression.
Hsp90 inhibitors such as geldanamycin, 17-AAG and
shepherdin have been shown effective in targeting the
Hsp90/survivin complex and subsequently inducing pro-
teasomal degradation of survivin [5,16-18].
Although it is widely believed that Hsp90 inhibitors
induce cancer cell death through indirect down-regula-
tion of survivin as one of its multiple therapeutic func-
tions, a study demonstrated that 17-AAG treatment
slightly increased the amount of survivin present in the
human DU145 prostate cancer cells [7]. However, the
mechanism of the over-expression of survivin in such cell
line was unknown. Interestingly, we also observed an up-
regulation of survivin in 17-AAG and geldanamycin-
treated human A549, HONE-1 and HT-29 cancer cells.
Since Hsp90 interferes with multiple molecules such as
sp1, sp3 (both transcriptional factors of survivin), and
26S proteasome (negative regulator of survivin protein
level) simultaneously [19,20], we hypothesize that target-
ing Hsp90 will affect the expression of survivin at various
stages. We also hypothesize that the use of Hsp90 inhibi-
tors may not be able to down-regulate survivin expres-
sion in certain cancer cells. Therefore, the purpose of this
study is to determine whether targeting Hsp90 can alter
survivin expression differently in different cancer cell
lines and to explore possible mechanisms that cause the
alteration in survivin expression.
Results
Targeting Hsp90 induces the over-expression of survivin in 
cancer cells
To determine whether the inhibition of Hsp90 with small
molecule inhibitors was able to affect survivin expression,
we treated human cancer cells with Hsp90 inhibitors
geldanamycin and 17-AAG. 17-AAG is a selective Hsp90
inhibitor that exhibited therapeutic activities in various
cancers and is currently undergoing phase III clinical tri-
als [17,21-24]. To ensure that both of our selected Hsp90
inhibitors were functioning normally at the molecular
level, HeLa cells (positive control) were incubated with
17-AAG and geldanamycin for 24 h and Western blot
analysis was used to determine the amount the survivin
presented in cells. Consistent with other studies, target-
ing Hsp90 with 17-AAG and geldanamycin (100 nM, 250
nM and 500 nM) reduced the amount of survivin
expressed in HeLa cells (Figure 1A) [5]. The effectiveness
of Hsp90 inhibitors was subsequently tested with the use
of the three-dimensional cell culturing system. Western
blot analysis revealed that the expression of survivin was
also down-regulated in three-dimensionally cultured
HeLa cells treated with 1 μM of 17-AAG for 24 h (Addi-
tional file 1).
To determine whether Hsp90 inhibitors were able to
down-regulation survivin in other cancer cell lines,
human A549, HT-29 and HONE-1 cancer cells were
used. In A549 cells, targeting Hsp90 with 17-AAG and
geldanamycin slightly induced the baseline expression of
Hsp90 as previously reported (Figure 1B) [5]. The same
treatment also induced down-regulation of both Akt and
phosporylated-Erk in human A549 (p53-mutant) lung
carcinoma cells as expected (Figure 1B) [7,25]. Together,
these results indicated that both Hsp90 inhibitors were
functioning normally at the molecular level. Surprisingly,
targeting Hsp90 with 17-AAG and geldanamycin did not
induce survivin down-regulation in A549 cancer cells.
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expression was induced by Hsp90 inhibitors in A549 cells
in a concentration-dependent manner (Figure 1B). In
addition, over-expression of survivin was shown in cells
treated with 17-AAG in a time-dependent manner (Fig-
ure 1C). Since clinical study of 17-AAG revealed that the
maximum peak serum level of this compound could
reach 2-3 μM, A549 cells were further treated with high
concentrations of 17-AAG and the expression of survivin
was determined. Over-expression of survivin was also
found in A549 cells treated with high concentrations (1
μM and 2 μM) of 17-AAG (Figure 1D). Moreover, West-
ern blot analysis revealed that the expression of survivin
was up-regulated in three-dimensionally cultured A549
cells treated with 1 μM of 17-AAG for 24 h (Additional
file 1).
The expression of survivin in Hsp90 inhibitors-treated
HONE-1 and HT-29 cells was determined by Western
blotting. Western blot analysis revealed that both 17-
AAG and geldanamycin treatments were able to induce
the over-expression survivin in HONE-1 (p53 wildtype)
nasopharyngeal carcinoma cells in a concentration-
dependent manner (Figure 2A). 17-AAG or geldanamy-
cin treated HT-29 (p53 mutant) colon adenocarcinoma
cells also over-expressed survivin (Figure 2B). In contrast,
17-AAG treatment was able to reduce the expression of
Figure 2 Over-expression of survivin in various 17-AAG/geldana-
mycin-treated human cancer cell lines. (A) Human HONE-1 cancer 
cells were treated with various concentrations of 17-AAG/geldanamy-
cin for 24 hours. Cell lysate was prepared after the treatment and vari-
ous proteins were resolved by SDS-PAGE. The expression of Akt and 
survivin was revealed by Western blot analysis. Actin was used as an in-
ternal control. Relative ratio of expression was shown. (B) Human HT-
29 cancer cells were treated with various concentrations of 17-AAG/
geldanamycin for 24 hours. Cell lysate was prepared after the treat-
ment and various proteins were resolved by SDS-PAGE. The expression 
of Akt and survivin was revealed by Western blot analysis. Actin was 
used as an internal control. Relative ratio of expression was shown.
Figure 1 Inhibition of Hsp90 with small molecule inhibitors in-
duces survivin over-expression in human A549 cancer cells. (A) 
Concentration-dependent down-regulation of survivin in drug-treat-
ed human HeLa cancer cells. HeLa cells were treated with DMSO or var-
ious concentrations (100 nM, 250 nM and 500 nM) of 17-AAG and 
geldanamycin for 24 hours. Cell lysate was prepared after the treat-
ment and various proteins were resolved by SDS-PAGE. (B) Concentra-
tion-dependent over-expression of survivin in drug-treated human 
A549 cancer cells. A549 cells were treated with DMSO or various con-
centrations (100 nM, 250 nM and 500 nM) of 17-AAG and geldanamy-
cin for 24 hours. Cell lysate was prepared after the treatment and 
various proteins were resolved by SDS-PAGE. The expression of Hsp90, 
Akt, phosphorylated-Erk and survivin was revealed by Western blot 
analysis. Actin was used as an internal control. Relative ratios of expres-
sion were shown. (C) Time-dependent over-expression of survivin in 
drug-treated human A549 cancer cells. Human A549 cells were treated 
with 500 nM of 17-AAG for various intervals. Cell lysate was prepared 
after the treatment and various proteins were resolved by SDS-PAGE. 
The expression of survivin was revealed by Western blot analysis. Actin 
was used as an internal control. (D) Over-expression of survivin in hu-
man A549 cells treated with high concentrations of 17-AAG. A549 cells 
were treated with 1-2 μM of 17-AAG for 24 hours. Cell lysate was ex-
tracted after the treatment and various proteins were resolved by SDS-
PAGE. Relative ratios of expression were shown.
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reported (Figures 2A and 2B) [7,25]. Taken together,
these data indicate that the surprising effect of Hsp90
inhibitors were specific to survivin in this study, as 17-
AAG and geldanamycin did not modulate the expression
of Hsp90, Akt and phosphorylated-Erk in A549 cells and
the expression of Akt in HONE-1 and HT-29 cells differ-
ently compared to the results of other studies. In three-
dimensional culture situations, Western blot analysis
revealed that 17-AAG treatment increased the amount of
survivin presented in HONE-1 and HT-29 cells (Addi-
tional file 1). These results suggest that down-regulation
of survivin is not a definite therapeutic effect induced by
Hsp90 inhibitors, as over-expression of survivin was
observed in cells treated with 17-AAG and geldanamycin
in this study.
Targeting Hsp90 induces the over-expression of survivin 
through a cell-cycle independent mechanism
It has been widely demonstrated that the expression of
survivin is tightly regulated during cell cycle and maxi-
mized during the G2/M phase. To determine whether the
over-expression of survivin in Hsp90-targeted cells was a
downstream result caused by cell cycle arrest at the G2/M
phase, flow cytometric analysis was performed. Interest-
ingly, 17-AAG treatment did not induce a uniform cell
cycle response among A549, HONE-1 and HT-29 cells.
Experimental results demonstrated that 500 nM of 17-
AAG induced cell cycle arrest of A549 cells at the G2/M
phase after 24 h (Figure 3). In contrast, the same treat-
ment induced S-phase arrest and G0/G1 phase cell cycle
arrest in HONE-1 and HT-29 cells respectively (Figure 3).
Taken together, results from both Western blot analysis
and flow cytometric analysis indicated that changes in
survivin expression in Hsp90-targeted cells were not
downstream results caused by cell cycle arrest at the G2/
M phase.
Targeting Hsp90 affects survivin expression at the 
transcriptional level
Since 17-AAG induced over-expression of survivin was
not an indirect result caused by cell cycle arrest, detailed
molecule mechanisms that govern survivin over-expres-
sion were investigated. It is widely believed that the
amount of protein presented in cells is tightly regulated
through the process of gene transcription, protein trans-
lation and protein degradation. To determine whether the
over-expression of survivin in Hsp90 inhibitor-treated
A549, HONE-1 and HT-29 cells was caused by changes at
the level of gene transcription, quantitative real-time
PCR was performed after 24 h post-treatment. In con-
trast to the result of Western blot analysis, a dose-depen-
dent decrease in the amount of survivin mRNA transcript
in 17-AAG-treated A549 cells was shown by real-time
PCR (Figure 4A). A general decrease in the amount of
survivin mRNA transcript was also shown in geldanamy-
cin-treated cells (Figure 4A). Cells treated with geldana-
mycin and 17-AAG showed reduced amount of survivin
mRNA by 45% (500 nM) and 75% (500 nM) respectively
in A549 cells, as compared to the control (Figure 4A).
However, phase-contrast microscopy did not reveal mor-
phological signs of death in Hsp90 inhibitors-treated cells
(Figure 4B). Therefore, both geldanamycin and 17-AAG
induced decreases in survivin mRNA instead of cell
death-induced global decreases at the total intracellular
mRNA level. These results also indicated that 17-AAG/
geldanamycin treatment increased the level of survivin
protein in cells possibly through transcription-indepen-
dent mechanism in A549 cancer cells. In contrast, 17-
AAG and geldanamycin treatment did not decrease the
amount of survivin RNA transcript present in HT-29 and
HONE-1 cells (Figure 4C and 4D). Instead, the same
treatment increased the level of survivin RNA in cells in a
dose-dependent manner. Thus, the effect induced by
Hsp90 inhibitors on the level of survivin gene transcrip-
tion seems to depend on the cellular context. Further-
more, the results suggest that increases in survivin
protein in response to Hsp90-targeted therapy in HT-29
Figure 3 17-AAG induces the over-expression of survivin through 
cell cycle-independent mechanism. A549 (A), HONE-1 (B) and HT-
29 (C) cells treated with 500 nM of 17-AAG for 24 h were stained with 
propidium iodide and subsequent analyzed by flow cytometry. Major 
changes in the cell cycle of 17-AAG-treated cells were highlighted in 
red color.
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vivin gene transcription. Taken together, these results
indicated that targeting Hsp90 with small molecule inhib-
itors might interfere with survivin gene transcription dif-
ferently in different cancer cells.
Targeting Hsp90 induces survivin expression through post-
transcriptional mechanisms
Since the above results revealed that changes at the level
of gene transcription did not contribute to the increase of
survivin protein in 17-AAG treated A549 cells, possible
post-transcriptional mechanisms such as protein transla-
tion and 26S proteasome-dependent protein degradation
were investigated in this cell line. To determine whether
17-AAG induced over-expression of survivin through
protein translation, translation inhibition study was per-
formed. Human A549 cancer cells were pre-incubated
with 500 nM of cycloheximide for three hours and subse-
quently treated with various concentrations of 17-AAG
for 24 hours. Cycloheximide is a translational inhibitor
that exerts its effect by interfering with the translocation
step in protein synthesis, thus blocking translational
elongation. Western blot analysis revealed dose-depen-
dent increases of survivin in the 17-AAG-treated A549
cancer cells (Figure 5A). Interestingly, cycloheximide
treatment completely abolished the dose-dependent pat-
tern of survivin expression in 17-AAG-treated cells (Fig-
ure 5A). However, the amount of survivin in
cycloheximide/17-AAG co-treated cells did not decrease
to the baseline level of the negative control (Figure 5A).
These results suggest that 17-AAG induces over-expres-
sion of survivin in A549 cancer cells partially through the
regulation of protein translation. Moreover, other post-
translational mechanisms may also contribute to the
over-expression of survivin in 17-AAG-treated cells.
To determine whether 17-AAG may interfere with the
stability of survivin protein in A549 cells, the rate of sur-
vivin protein degradation was determined in cells treated
with/without 17-AAG. Cells were pre-incubated with 500
nM of cyclohexmide for one hour and subsequently co-
incubated with 17-AAG for various time. Western blot
analysis revealed that the degradation rate of survivin
protein was slightly slower in 17-AAG treated A549 cells
than the untreated cells (Figure 5B). The amount of sur-
vivin protein presented in 17-AAG untreated-cells was
reduced by 70% after 4 h of protein synthesis inhibition
(Figure 5C). In contrast, the amount of survivin presented
in 17-AAG-treated cells was reduced by only 20% at the
same time point (Figure 5C). Thus, the reduced rate of
protein degradation might also contribute to the
increased amount of survivin protein presented in 17-
AAG treated A549 cancer cells.
Figure 4 17-AAG treatment induces over-expression of survivin 
through transcription-independent mechanisms. (A) Inhibition of 
Hsp90 reduced the amount of survivin mRNA transcript presented in 
17-AAG treated A549 cells. Human A549 cancer cells were incubated 
with DMSO (negative control) or various concentrations (10 nM, 100 
nM, 250 nM and 500 nM) of 17-AAG and geldanamycin for 24 hours. 
Quantitative RT-PCR was performed to determine the amount of sur-
vivin transcripts presented in cells. (B) Cells treated with 17-AAG and 
geldanamycin did not induce abnormal cell morphology. A549 cells 
incubated with various concentrations (250 nM and 500 nM) of 17-
AAG and geldanamycin for 24 hours and cell morphology was re-
vealed by phase-contrast microscopy. (C) Inhibition of Hsp90 in-
creased the amount of survivin mRNA transcript presented in 17-AAG 
and geldanamycin treated HT-29 cells. HT-29 cells were incubated 
with DMSO (negative control) or various concentrations (10 nM, 100 
nM, 250 nM and 500 nM) of 17-AAG for 24 hours. Quantitative RT-PCR 
was performed to determine the amount of survivin transcripts pre-
sented in cells. (D) Inhibition of Hsp90 increased the amount of sur-
vivin mRNA transcript presented in 17-AAG treated HONE-1 cells. 
HONE-1 cells were incubated with DMSO (negative control) or various 
concentrations (10 nM, 100 nM, 250 nM and 500 nM) of 17-AAG for 24 
hours. Quantitative RT-PCR was performed to determine the amount 
of survivin transcripts presented in cells.
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in cancer cells
Survivin is normally degraded through the proteasomal
degradation pathway and it has been shown that the 26S
proteasome is responsible for this process [26]. On the
other hand, Hsp90 plays a role in the assembly and main-
tenance of the 26S proteasome [20]. Furthermore,
reduced proteasomal activity has been shown in 17-AAG
and geldanamycin-treated cells [27,28]. Here, protea-
some-dependent protein degradation pathway was inves-
tigated to determine whether proteasome plays a role in
the reduced survivin degradation rate in 17-AAG treated
A549, HONE-1 and HT-29 cells. In our study, Western
blot analysis revealed that 17-AAG reduced the amount
of 26S proteasome presented in A549 cells (Figure 6A). In
addition, proteasomal activity assay also revealed that the
activity of 26S proteasome was reduced by 25-30% in cells
treated with 17-AAG (Figure 6B). To demonstrate that
inhibition of 26S proteasome would subsequently affect
the amount of survivin expressed in cells, the 26S protea-
some inhibitor MG-132 was used. Western blot analysis
clearly revealed that inhibition of the proteasomal activity
by MG-132 induced survivin over-expression in a con-
centration-dependent manner (Figure 6C). Together with
the results from the protein degradation experiment,
these data suggest that increased survivin levels in A549
cells cannot simply be attributed to the induction of pro-
tein translation. Post-translational mechanisms such as
the regulation of the 26S proteasome-dependent protein
degradation may also play a role in survivin over-expres-
sion in 17-AAG treated A549 cells.
To determine whether proteasomal activity was also
affected in 17-AAG treated HT-29 and HONE-1 cells,
proteasomal activity of drug-treated cells was measured.
Proteasomal activity assay revealed that the activity of
26S proteasome was reduced by ~20% in HT-29 and
HONE-1 cells treated with 17-AAG (Figure 7A). In addi-
tion, Western blot analysis revealed co-treatment of 17-
AAG and the proteasome inhibitor, MG-132, induced
synergistic increases in the level of survivin present in
both cell lines (Figure 7B). These results indicated that
the inhibition of 26S proteasome might also play a role in
the up-regulation of survivin in 17-AAG treated HT-29
and HONE-1 cells.
Targeting survivin increases drug sensitivity to 17-AAG in 
cancer cells
It has been shown that silencing of survivin gene by small
interfering RNAs produces supra-additive growth sup-
pression in combination with 17-AAG in human prostate
cancer cells [18]. To determine the functional importance
of survivin in interfering with drug sensitivity to Hsp90
inhibitors in A549, HONE-1 and HT-29 cells, survivin
was down-regulated by siRNA and cell viability was mea-
Figure 5 Hsp90 inhibition induced over-expression of survivin 
through post-transcriptional mechanisms in A549 cells. (A) Hsp90 
inhibition induced over-expression of survivin partially through the 
process of protein translation. A549 cells were pre-incubated with/
without 500 nM of cycloheximide for 1 hour and subsequently treated 
with DMSO or various concentrations (100 nM, 250 nM and 500 nM) of 
17-AAG 24 hours. The expression of survivin was revealed by Western 
blot analysis. Actin was used as an internal control. Relative ratio of ex-
pression was shown. (B) 17-AAG reduced the rate of survivin protein 
degradation in A549 cells. A549 cells were pre-incubated with 500 nM 
of cycloheximide for 1 hour and subsequently treated with/without 
250 nM of 17-AAG for various time. The expression of survivin was re-
vealed by Western blot analysis. Actin was used as an internal control. 
Relative ratio of expression was shown. (C) The amount of survivin pre-
sented in un-treated A549 cells was less than that in 17-AAG-treated 
cells after 4 hours of protein synthesis inhibition. A549 cells were pre-
incubated with 500 nM of cycloheximide for 1 hour and subsequently 
treated with/without 250 nM of 17-AAG for 2 hours and 4 hours. The 
expression of survivin was revealed by Western blot analysis. Actin was 
used as an internal control. Relative ratio of expression was shown.
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specific siRNA oligomer (siR-S) or scramble oligomer
(siR-C) for 48 h and sub-subsequently incubated with/
without 250 nM of 17-AAG for 24 h. Cells viability assay
revealed that A549, HT-29 and HONE-1 cells treated
with 250 nM of 17-AAG did not show reduced viability as
compared to cells treated with DMSO (Figure 8). In addi-
tion, down-regulation of survivin by siR-S significantly
reduced cell viability by ~30% in both cell lines as com-
pared to cells transfected with control oligomer, siR-C
(Figure 8). Interestingly, siR-S/17-AAG combination
treatment further reduced the cell viability of A549, HT-
29 and HONE-1 as compared to 17-AAG mono-treat-
ment (Figure 8). Taken together, our results indicate that
survivin plays an important role in the sensitivity to the
Hsp90 inhibitor, 17-AAG, in our tested cancer cell lines.
Discussion
It is widely believed that targeting Hsp90 with small mol-
ecule inhibitors is able to directly interfere with the phys-
ical interaction between Hsp90 and survivin, leading to
the decrease of survivin protein level and induction of
cancer cell death [5,15]. Interestingly, this study demon-
strated for the first time that targeting Hsp90 with small
Figure 6 17-AAG interfered with the amount and activity of 26S 
proteasome in A549 cells. (A) 17-AAG treatment reduced the 
amount of 26S proteasome presented in A549 cells. A549 cells were 
treated with DMSO and various concentrations (100 nM, 250 nM and 
500 nM) of 17-AAG for 24 hours. The expression of 26S proteasome 
was revealed by Western blot analysis. Actin was used as an internal 
control. Relative ratio of expression was shown. (B) Inhibition of Hsp90 
with 17-AAG reduced proteasome activity in A549 cells. Cells were 
treated with various concentrations of 17-AAG and 4 μM of MG-132 
(positive control) for 24 h. Cells were washed with PBS and lysed with 
TNESV buffer without protease inhibitor. Cell lysate were analyzed for 
proteasome activity using synthetic fluorogenic peptide succinyl-Leu-
Leu-Val-Tyr-7-amino-4-methylcoumarin. Statistical significance (p < 
0.05) between experimental samples and the DMSO control is denot-
ed by "*". (C) Inhibition of 26S proteasome increased the amount of 
survivin in A549 cells. A549 cells were treated with DMSO and various 
concentrations (1000 nM, 2000 nM, 4000 nM and 8000 nM) of the 26S 
proteasome inhibitor, MG-132, for 24 hours. The expression of survivin 
was revealed by Western blot analysis. Actin was used as an internal 
control. Relative ratio of expression was shown.
Figure 7 Inhibition of Hsp90 with 17-AAG reduced proteasome 
activity in HONE-1 and HT-29 cells. (A) Cells were treated with vari-
ous concentrations of 17-AAG for 24 h. Cells were washed with PBS 
and lysed with TNESV buffer without protease inhibitor. Cell lysate 
were analyzed for proteasome activity using synthetic fluorogenic 
peptide succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin. Statisti-
cal significance (p < 0.05) between experimental samples and the 
DMSO control is denoted by "*". (B) Inhibition of 26S proteasome fur-
ther increased the amount of survivin protein in 17-AAG treated 
HONE-1 and HT-29 cells. Cells were treated with DMSO and various 
concentrations (100 nM, 250 nM, 500 nM) of 17-AAG with/without MG-
132 for 24 hours. The expression of survivin was revealed by Western 
blot analysis. Actin was used as an internal control.
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at various stages, resulting in an increase of the amount of
survivin protein presented in cancer cells. Furthermore,
this study demonstrated that survivin plays an important
role in the sensitivity to the Hsp90 inhibitor, 17-AAG, in
cancer cells.
Here, we showed that targeting Hsp90 with small mole-
cule inhibitor affected the amount of survivin mRNA
transcript presented in cancer cells. It is not surprising
that targeting Hsp90 induces different effect at the level
of gene transcription in different cancer cells. Literatures
revealed that the rate of survivin gene transcription is
positively regulated by molecules such as sp1, sp3 and
Myc [29,30]. In contrast, the gene transcription process
of survivin is negatively regulated by molecules such as
p53, retinoblastoma (Rb) and prostate-derived Ets tran-
scription factor (PDEF) [31-33]. Importantly, Hsp90
interferes with sp1, sp3, p53 and Rb simultaneously
[34,35]. Hence, differences in the response of survivin
gene transcription may reflect different dependencies of
various Hsp90-interfered and Hsp90-unrelated transcrip-
tional factors on the expression of survivin in different
cell types. Therefore, depending on the cellular context,
targeting Hsp90 might indirectly up-regulate/down-regu-
late the process of survivin gene transcription through
the interference with various survivin-related transcrip-
tional factors.
Interestingly, our data also demonstrated that decreases
at the mRNA level did not translate into decreases in sur-
vivin protein level in 17-AAG treated A549 cells.
Together with results from the translation inhibition
experiment, the protein degradation experiment and the
examination of the survivin-related 26S proteasome, the
current study strongly indicates that Hsp90 also inter-
feres with survivin expression at the post-transcriptional
level. Thus, Hsp90-targeted treatment interferes with the
process of survivin gene transcription, protein translation
and protein degradation simultaneously. In fact, Hsp90
plays an important role in the assembly and maintenance
of the 26S proteasome [20,36]. The activity of 26S protea-
some was shown to be reduced by the addition of the
Hsp90 inhibitor, geldanaymicin, in vitro [20]. Reduced
proteasomal activity was also shown previously in Hsp90-
inhibited multiple myeloma cells [27]. On the other hand,
previous studies demonstrated that indomethacin
(NASID) and chlamydocin (HDAC inhibitor) enhanced
survivin degradation through ubiquitin proteasome
machinery in cells [37,38]. In our study, the use of protea-
some inhibitor MG-132 was shown effective in increasing
the amount of survivin present in our tested cancer cell
lines, indicating that the activity of proteasome was
important for survivin regulation. Therefore, the level of
activity of proteasome might be one of the determinants
of the amount of survivin present in Hsp90-inhibited
cancer cells. However, it is hard to determine whether the
interference with proteasome plays the most important
role in the up-regulation of survivin. Further investiga-
tions are needed to determine the relative importance of
transcription, translation and proteasome-related protein
degradation in different Hsp90-targeted cancer cells. It is
also worth noting that both 17-AAG and geldanamycin
treatment reduced the amount of survivin presented in
HeLa cells and this result was consistent with other stud-
ies. In contrast, results of the 3D-culture model revealed
that 17-AAG treatment (1 μM) was also able to induce
the over-expression of survivin in three dimensional cul-
Figure 8 Down-regulation of survivin enhanced the sensitivity to 
Hsp90 inhibitor in various cancer cells. A549 (A), HT-29 (B) and 
HONE-1 (C) cells were transfected with siR-C (scramble control) and 
siR-S (survivin specific) siRNA oligomers for 48 h and subsequently in-
cubated with/without 250 nM of 17-AAG for 24 h. MTT cell viability as-
say was used to determine the viability of various treatments treated 
cells. Statistical significance (p < 0.05) between experimental samples 
is denoted by "*".
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Thus, the current study indicates that targeting Hsp90
may induce cell line-specific responses in the expression
of survivin.
Importantly, results of the current study raise the con-
cern that Hsp90 inhibitors might not function in a way as
we previously thought. Indeed, literature reported that
17-AAG promoted formation of osteolytic lesions and
bone metastases in murine breast cancer model, even
though the drug reduced tumor growth at the orthotopic
site [39]. Furthermore, Kayani et al. demonstrated that
17-AAG treatment was able to enhance the expression of
Hsp70 in C2C12 muscle fiber cells and the recovery of
extensor digitorum longus (EDL) following lengthening
contraction-induced damage in animal model [40]. Thus,
targeting Hsp90 with small molecular inhibitors may not
be able to induce cell death in certain circumstances.
Conclusion
In conclusion, the current study reveals the complex
interaction between Hsp90 and survivin in cancer cells.
Besides stabilizing the survivin protein through simple
physical interaction, Hsp90 also indirectly interferes with
survivin expression through transcription, translation
and proteasome-related protein degradation. These novel
findings suggest a model in which gene transcription,
together with protein translation and proteasomal degra-
dation, constitute a platform capable of modulating the
amount of survivin expressed in Hsp90-targeted cancer
cells. Our findings suggest that down-regulation of sur-
vivin is not a definitive therapeutic function of Hsp90
inhibitors and that dual inhibition of Hsp90 and survivin
may be warranted.
Materials and methods
Cell lines, antibodies and reagents
The human lung carcinoma (A549), nasopharyngeal car-
cinoma (HONE-1) and colorectal adenocarcinoma (HT-
29) cells were purchased from the American Type Cul-
ture Collection (ATCC, Manassas, VA). A549 cells were
cultured in RPMI 1640 medium (Gibco, Grand Island,
NY), supplemented with 10% fetal bovine serum, penicil-
lin (100 U/mL), streptomycin (100 μg/mL) and L-glu-
tamine (0.29 mg/mL), at 37°C. HONE-1 and HT-29 cells
were cultured in RPMI 1640 medium (Gibco, Grand
Island, NY), supplemented with 5% fetal bovine serum,
penicillin (100 U/mL), streptomycin (100 μg/mL) and L-
glutamine (0.29 mg/mL), at 37°C. The antibodies used in
this study included a mouse anti-Actin antibody (Santa
Cruz Biotechnology, Santa Cruz, CA), a rabbit anti-Sur-
vivin antibody (R&D Systems, Minneapolis, MN), a rab-
bit anti-Akt antibody (Cell Signaling Technology,
Danvers, MA) and a mouse anti-26S proteasome anti-
body (abcam, Cambridge, UK). Hsp90 inhibitors used in
this study included: 17-AAG (Calbiochem, Darmstadt,
Germany), geldanamycin (Calbiochem, Darmstadt, Ger-
many) and cycloheximide (Calbiochem, Darmstadt, Ger-
many).
Real-time reverse transcription-polymerase chain reaction 
(Real-time PCR)
Expression level of survivin transcript was determined by
real-time reverse transcriptase (RT)-polymerase chain
reaction (PCR) using a LightCycler instrument (Roche,
Indianapolis, IN). Primers and Taqman probes were
designed by Probe Finder™ http://www.universalprobeli-
brary.com. Taqman probes were from the Universal
Probe Library: survivin and hGAPDH. Specific primers
with following sequences were used: survinin forward, 5'
GCCCAGTGTTTCTTCTGCTT; Survivin reverse, 5'CC
GGACGAATGCTTTTTATG; hGAPDH forward, 5' AG
CCACATCGCTCAGACAC and hGAPDH reverse, 5' G
CCCAATACGACCAAATCC. The real-time PCR condi-
tion was as follows: 1 cycle of initial denaturation at 95°C
for 10 min, 45 cycles of amplification at 95°C for 10 s,
60°C for 30 s, and 72°C for 1 s, with a single fluorescence
acquisition. hGAPDH gene was used as an internal con-
trol. All experiments have been repeated twice.
SDS-PAGE and Western blot analysis
Cells were lysed with ice-cold lysis buffer (10 mM Tris, 1
mM EDTA, 1 mM DTT, 60 mM KCl, 0.5% NP-40 and
protease inhibitors). Total cell lysates, fractions of super-
natant or pellet were resolved on 10% and 12% polyacryl-
amide SDS gels under reducing conditions. The resolved-
proteins were electrophoretically transferred to PVDF
membranes (Amersham Life Science, Amersham, U.K.)
for Western blot analysis. The membranes were blocked
with 5% non-fat milk powder at room temperature for
two hours, washed twice with PBST (1% Tween) and then
incubated with primary antibody for 90 minutes at room
temperature. The membranes were washed twice with
PBST then subsequently incubated with a horseradish
peroxidase-conjugated secondary antibody (dilution at
1:10000, Santa Cruz Biotechnology, Santa Cruz, CA).
Immunoreactivity was detected by Enhanced Chemilu-
minescence (Amersham International, Buckingham,
U.K.) and autoradiography. All experiments have been
repeated twice.
Proteasome activity assay
Cells exposed to various concentrations of 17-AAG and
MG-132 for 24 h were washed twice with PBS and lysed
with TNESV buffer [50 mM Tris-HCl (pH 7.5), 1% NP40
detergent, 2 mM EDTA, 100 mM NaCl, 10 mM sodium
orthovanadate] without protease inhibitors. Cell lysate
were assayed for proteasome chymotrypsin activity using
the synthetic fluorogenic peptide chymotrypsin sub-
strate, N-Succinyl-Leu-Leu-Val-Tyr-AMC. Fluorescent
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Page 10 of 11signals were measured with a 96-well plate reader with an
excitation wavelength of 380 nm and emission wave-
length of 460 nm. All experiments have been performed
as triplicate and repeated twice.
siRNA
Target-validated siRNA oligos (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) were transfected into cells using the
Lipofectamine-2000 reagent (Invitrogen, Carlsbad, CA).
Briefly, cells were seeded onto 96-well plates or chamber-
slides, and cultured overnight in 100 μl of antibiotic-free
RPMI media. siRNA oligomers (8 pmol in 0.4 μl) were
diluted in 25 μl of Opti-MEM® I medium (Invitrogen,
Carlsbad, CA) without serum, and then mixed with 0.2 μl
of Lipofectamine-2000 transfection reagent for 25 min at
room temperature. Cells were overlaid with the transfec-
tion mixture, and incubated for various times.
MTT cell viability assay
Cells seeded onto 96-well plates were transfected with/
without survivin-specific siRNA oligomer for 48 h and
subsequently treated with 17-AAG for 24 h. 25 μl of MTT
(5 mg/mL) was added to each sample and incubated for 4
hours, under 5% CO2 and 37°C. 100 μl of lysis buffer (20%
SDS, 50% DMF) was subsequently added into each sam-
ple and further reacted for 16 hours.
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